Skip to main content

Drug Interactions between sildenafil and st. john's wort

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

sildenafil St. John's wort

Applies to: sildenafil and st. john's wort

ADJUST DOSE: Coadministration with moderate to potent CYP450 3A4 inducers may significantly decrease the plasma concentrations and effects of sildenafil, which is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C9. This interaction has been demonstrated in studies using bosentan, a moderate CYP450 3A4 inducer and weak CYP450 2C9 inducer in vivo as well as an in vitro inducer of CYP450 2C19. Coadministration of oral sildenafil (80 mg three times daily) at steady state with bosentan (125 mg twice daily) at steady state over 6 days in healthy adult volunteers decreased the systemic exposure (AUC) and peak plasma concentration (Cmax) of sildenafil by 62.6% and 55.4%, respectively. The same effect was also observed with lower doses of oral sildenafil (20 mg three times daily) added to bosentan therapy (62.5 mg - 125 mg twice daily). The labeling for some sildenafil formulations used for pulmonary arterial hypertension (PAH) reported a population pharmacokinetic analysis of data from patients in clinical trials which indicated an approximately 3-fold increase in sildenafil clearance when co-administered with mild CYP450 3A4 inducers. However, this increased clearance was not reflected in a population pharmacokinetic analysis described in the labeling of some sildenafil formulations indicated for erectile dysfunction. More potent CYP450 3A4 inducers are expected to have greater effects than those observed with bosentan or mild inducers; however, data are not available. Likewise, clinical data regarding this interaction in pediatric patients are also unavailable.

MANAGEMENT: In adult patients being treated for pulmonary arterial hypertension (PAH), the dose of sildenafil may need to be increased when initiating treatment with moderate to potent CYP450 3A4 inducers. Conversely, the manufacturer recommends reducing the dose of sildenafil to 20 mg orally three times daily when discontinuing treatment with moderate to potent CYP450 3A4 inducers. Patients being treated for erectile dysfunction should be monitored closely and may require a dose adjustment of sildenafil if a moderate or strong CYP450 3A4 inducer is initiated or discontinued. Dosing should be guided by the patient's symptoms, ability to tolerate sildenafil, and recommendations provided in the product labeling.

References (14)
  1. Warrington JS, Shader RI, vonMoltke LL, Greenblatt DJ (2000) "In vitro biotransformation of sildenafil (Viagra): Identification of human cytochromes and potential drug interactions." Drug Metab Disposition, 28, p. 392-7
  2. Hyland R, Roe GH, Jones BC, Smith DA (2001) "Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil." Br J Clin Pharmaacol, 51, p. 239-48
  3. (2023) "Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group, SUPPL-25
  4. (2023) "Product Information. Revatio (sildenafil)." Pfizer Australia Pty Ltd
  5. (2021) "Product Information. Wafesil (sildenafil)." iX Biopharma Pty Ltd
  6. (2021) "Product Information. Silcap (sildenafil)." iX Biopharma Pty Ltd
  7. (2023) "Product Information. Viagra Connect (sildenafil)." Viatris UK Healthcare Ltd
  8. (2023) "Product Information. Revatio (sildenafil)." Pfizer Ltd
  9. (2022) "Product Information. Sildenafil (sildenafil)." Rosemont Pharmaceuticals Ltd
  10. (2022) "Product Information. Sildenafil (Lupin) (sildenafil)." Generic Health Pty Ltd, v1
  11. (2021) "Product Information. Revatio (sildenafil)." Pfizer Canada Inc
  12. (2022) "Product Information. Priva-Sildenafil (sildenafil)." Pharmapar Inc
  13. (2023) "Product Information. Sildenafil (sildenafil)." Amarox Ltd
  14. (2022) "Product Information. Sildenafil Citrate (sildenafil)." Torrent Pharma Inc

Drug and food interactions

Moderate

sildenafil food

Applies to: sildenafil

GENERALLY AVOID: Coadministration with grapefruit juice may slightly increase the oral bioavailability and delay the onset of action of sildenafil. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruits. In a randomized, crossover study with 24 healthy male volunteers, ingestion of 250 mL of grapefruit juice one hour before and concurrently with a 50 mg dose of sildenafil increased the mean area under the plasma concentration-time curve (AUC) of sildenafil and its pharmacologically active N-desmethyl metabolite by 23% and 24%, respectively, compared to water. Peak plasma concentrations (Cmax) were unaltered, but the time to reach sildenafil Cmax was prolonged by 0.25 hour. The observed increase in sildenafil bioavailability is unlikely to be of clinical significance in most individuals. However, pharmacokinetic interactions involving grapefruit juice are often subject to a high degree of interpatient variability and may be significant in the occasional susceptible patient. Indeed, one subject in the study had a 2.6-fold increase in sildenafil concentrations.

MANAGEMENT: It may be advisable to avoid administration of sildenafil with grapefruit juice to prevent potential toxicity and delay in onset of action.

References (1)
  1. Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. (2002) "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther, 71, p. 21-29
Moderate

St. John's wort food

Applies to: st. john's wort

GENERALLY AVOID: An isolated case report suggests that foods containing large amounts of tyramine may precipitate a hypertensive crisis in patients treated with St. John's wort. The mechanism of interaction is unknown, as St. John's wort is not thought to possess monoamine oxidase (MAO) inhibiting activity at concentrations achieved in vivo. The case patient was a 41-year-old man who had been taking St. John's wort for seven days prior to presentation at the emergency room with confusion and disorientation. The patient recalled last eating aged cheese and having a glass of red wine approximately 10 hours prior to admission. No other cause of delirium or hypertension could be identified. In addition, alcohol may potentiate some of the pharmacologic effects of St. John's wort. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Until further information is available, patients treated with St. John's wort should consider avoiding consumption of protein foods in which aging or breakdown of protein is used to increase flavor. These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, yogurt, papaya products, meat tenderizers, fava beans, protein extracts, and dietary supplements. Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well. Patients should also be advised to avoid or limit consumption of alcohol.

References (1)
  1. Patel S, Robinson R, Burk M (2002) "Hypertensive crisis associated with St. John's Wort." Am J Med, 112, p. 507-8

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.